BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu Y, He J, Geng J, An Y, Ye X, Yan S, Yu Q, Yin J, Zhang Z, Li D. Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy. Eur J Pharmacol 2017;802:85-92. [PMID: 28246027 DOI: 10.1016/j.ejphar.2017.02.042] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Ji Q, Wu Y, Albers A, Fang M, Qian X. Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches. Pharmaceutics 2022;14:1811. [DOI: 10.3390/pharmaceutics14091811] [Reference Citation Analysis]
2 Huang F, Dai C, Zhang Y, Zhao Y, Wang Y, Ru G. Development of Molecular Mechanisms and Their Application on Oncolytic Newcastle Disease Virus in Cancer Therapy. Front Mol Biosci 2022;9:889403. [DOI: 10.3389/fmolb.2022.889403] [Reference Citation Analysis]
3 bin Umair M, Akusa FN, Kashif H, Seerat-e-fatima, Butt F, Azhar M, Munir I, Ahmed M, Khalil W, Sharyar H, Rafique S, Shahid M, Afzal S. Viruses as tools in gene therapy, vaccine development, and cancer treatment. Arch Virol. [DOI: 10.1007/s00705-022-05432-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Meng Q, He J, Zhong L, Zhao Y. Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus. Int J Med Sci 2021;18:2294-302. [PMID: 33967605 DOI: 10.7150/ijms.59185] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
5 Diaz Arguello OA, Haisma HJ. Apoptosis-Inducing TNF Superfamily Ligands for Cancer Therapy. Cancers (Basel) 2021;13:1543. [PMID: 33801589 DOI: 10.3390/cancers13071543] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zhang S, Rabkin SD. The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy? Expert Opin Drug Discov 2021;16:391-410. [PMID: 33232188 DOI: 10.1080/17460441.2021.1850689] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
7 Jamieson TR, Poutou J, Ilkow CS. Redirecting oncolytic viruses: Engineering opportunists to take control of the tumour microenvironment. Cytokine & Growth Factor Reviews 2020;56:102-14. [DOI: 10.1016/j.cytogfr.2020.07.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 He J, An Y, Qi J, Cui L, Yang K, Liu M, Qu B, Yan S, Yin J, Jing X, Dong H, Yu Q, Li D, Wu Y. The recombinant Newcastle disease virus Anhinga strain expressing human TRAIL exhibit antitumor effects on a glioma nude mice model. J Med Virol 2021;93:3890-8. [PMID: 32779745 DOI: 10.1002/jmv.26419] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
9 Hromic-Jahjefendic A, Lundstrom K. Viral Vector-Based Melanoma Gene Therapy. Biomedicines 2020;8:E60. [PMID: 32187995 DOI: 10.3390/biomedicines8030060] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
10 Zheng M, Huang J, Tong A, Yang H. Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances.Mol Ther Oncolytics. 2019;15:234-247. [PMID: 31872046 DOI: 10.1016/j.omto.2019.10.007] [Cited by in Crossref: 92] [Cited by in F6Publishing: 82] [Article Influence: 30.7] [Reference Citation Analysis]
11 Xu X, Yi C, Yang X, Xu J, Sun Q, Liu Y, Zhao L. Tumor Cells Modified with Newcastle Disease Virus Expressing IL-24 as a Cancer Vaccine. Mol Ther Oncolytics 2019;14:213-21. [PMID: 31338417 DOI: 10.1016/j.omto.2019.06.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
12 Wei D, Xu J, Liu XY, Chen ZN, Bian H. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China. Hum Gene Ther 2018;29:151-9. [PMID: 29284308 DOI: 10.1089/hum.2017.212] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
13 Lundstrom K. RNA Viruses as Tools in Gene Therapy and Vaccine Development. Genes (Basel) 2019;10:E189. [PMID: 30832256 DOI: 10.3390/genes10030189] [Cited by in Crossref: 21] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
14 Hu H, Roth JP, Yu Q. Generation of a recombinant Newcastle disease virus expressing two foreign genes for use as a multivalent vaccine and gene therapy vector. Vaccine 2018;36:4846-50. [PMID: 30037477 DOI: 10.1016/j.vaccine.2018.06.055] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
15 Lundstrom K. Viral Vectors in Gene Therapy. Diseases. 2018;6. [PMID: 29883422 DOI: 10.3390/diseases6020042] [Cited by in Crossref: 175] [Cited by in F6Publishing: 191] [Article Influence: 43.8] [Reference Citation Analysis]
16 Lundstrom K. New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy. Biologics. 2018;12:43-60. [PMID: 29445265 DOI: 10.2147/btt.s140114] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]